Please login to the form below

Not currently logged in

AZ prices severe asthma drug Fasenra below competition

AstraZeneca AZ

The discounted drug will cost $38,000 in the first year

Loxo’s cancer drug pair attracts $1.5bn deal with Bayer

Bayer - research centre BerlinThe German pharma group will gain full rights to the drugs outside the US

Fujifilm expands biopharma development and manufacturing business

SiteCompany invests 3.2bn yen in US and UK sites

Sanofi licences Principia MS drug in $805m deal

Sanofi receptionCalifornian biotech is set to receive $765m plus in milestone payments if PRN2246 goes to market

QuintilesIMS changes its name to IQVIA

IQVIAFirm will focus on human data science solutions

GSK to replace R&D head Vallance with Calico’s Hal Barron

GSK - logo on buildingBarron will also hold an executive director position on GSK’s board

Novartis files CAR-T therapy CTL109 in Europe

Novartis HQAnalysts predict Kymriah could become a $1bn-plus product in Europe

Vertex's tezacaftor/ivacaftor shows lung function boost

Vertex PharmaThe combination therapy is currently under review in Europe and the US

GSK’s R&D head Vallance departs, possibly for government role

GSK - logo on buildingAn independent panel of scientists proposed the UK role to Vallance, according to the FT

Ho_Ung_KimStanding out in a crowd

Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

Featured jobs

Subscribe to our email news alerts


Add my company

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

Shining a light on the true cost of patient care
Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore how the proposed national patient data sharing scheme would change the NHS...
The real-world data conundrum
How data is changing the healthcare industries...
Where is health behaviour change heading?
Cures rely on patient adherence to succeed, and health behaviour change in any non-compliant patient is essential, this post explores where health behaviour change is heading....